Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:815013.
doi: 10.5402/2011/815013. Epub 2011 Nov 17.

Multiple myeloma and diabetes

Zeinab A Issa  1 , Mira S Zantout, Sami T Azar
Affiliations

Multiple myeloma and diabetes

Zeinab A Issa et al. ISRN Endocrinol. 2011.

Abstract

Multiple myeloma is a malignant plasma cell disorder that accounts for approximately 10% of all hematologic cancers. It is characterized by accumulation of clonal plasma cells, predominantly in the bone marrow. The prevalence of type 2 diabetes is increasing; therefore, it is expected that there will be an increase in the diagnosis of multiple myeloma with concomitant diabetes mellitus. The treatment of multiple myeloma and diabetes mellitus is multifaceted. The coexistence of the two conditions in a patient forms a major challenge for physicians.

PubMed Disclaimer

References

    1. Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum. 2006;19(3):157–162.
    1. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clinic Proceedings. 2005;80(10):1371–1382. - PubMed
    1. Jagannath S. Treatment of patients with myeloma with comorbid conditions: considerations for the clinician. Clinical Lymphoma and Myeloma. 2008;8(4, supplement):S149–S156. - PubMed
    1. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nature Clinical Practice Oncology. 2005;2(1):48–53. - PubMed
    1. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. British Journal of Haematology. 2009;144(6):895–903. - PubMed

LinkOut - more resources